Connect with us

Technology

Pharmaceutical Contract Research and Manufacturing Market to grow by USD 141.3Billion from 2024-2028, driven by cost-efficient resources in emerging markets, AI-powered report – Technavio

Published

3 months ago

on

NEW YORK, Oct. 7, 2024 /PRNewswire/ — Report on how AI is driving market transformation – The Global Pharmaceutical Contract Research and Manufacturing Market size is estimated to grow by USD 141.3 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  10.87%  during the forecast period. Availability of cost-efficient resources in emerging markets is driving market growth, with a trend towards increasing number of US FDA approved manufacturing facilities. However, stereotypical nature of CMOS  poses a challenge – Key market players include Almac Group Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Catalent Inc., Charles River Laboratories International Inc., Cmic Holdings Co. Ltd, Dr Reddys Laboratories Ltd., ICON plc, IQVIA Holdings Inc., Laboratory Corp. Of America Holdings, Lonza Group Ltd., Lupin Ltd., Novotech Health Holdings, OPTIMAPHARM d.o.o., Parexel International Corp., PCI Pharma Services, Recipharm AB, Samsung Electronics Co. Ltd., Syneos Health Inc., and Thermo Fisher Scientific Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report

Pharmaceutical Contract Research And Manufacturing Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 10.87%

Market growth 2024-2028

USD 141.3 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

9.51

Regional analysis

North America, Asia, Europe, and Rest of World (ROW)

Performing market contribution

Asia at 46%

Key countries

US, China, India, Germany, and UK

Key companies profiled

Almac Group Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Catalent Inc., Charles River Laboratories International Inc., Cmic Holdings Co. Ltd, Dr Reddys Laboratories Ltd., ICON plc, IQVIA Holdings Inc., Laboratory Corp. Of America Holdings, Lonza Group Ltd., Lupin Ltd., Novotech Health Holdings, OPTIMAPHARM d.o.o., Parexel International Corp., PCI Pharma Services, Recipharm AB, Samsung Electronics Co. Ltd., Syneos Health Inc., and Thermo Fisher Scientific Inc.

Market Driver

The Pharmaceutical Contract Research and Manufacturing (CRAM) market is experiencing significant growth due to the increasing number of US FDA-approved manufacturing facilities in emerging economies, particularly China and India. India, with around 400 such facilities, is a top destination for pharmaceutical manufacturing services outsourcing. This includes approximately 230 API and 150 FDF facilities, the highest in any country. China, previously limited to CROs due to stringent regulations on CMOS, has seen a shift with the State Council allowing MAHs to use third-party licensed manufacturers. This change has led to an increase in US FDA-approved facilities and foreign pharmaceutical companies outsourcing drug manufacturing to China. This trend is expected to continue, driving the growth of the global pharmaceutical CRAM market.

The Pharmaceutical Contract Research and Manufacturing (CRM) market is witnessing significant trends in various areas. Generic Drugs are gaining popularity due to their affordability, driving demand for Generic APIs and Formulation Services. Artificial Intelligence is revolutionizing Drug Discovery and Development, enabling faster identification of Drug Candidates. Route Scouting Services and Bioprocess Outsourcing are key areas of focus for Biologics Manufacturing. Regulatory Compliance remains a top priority, with Serialization and Counterfeiting mitigation measures essential. Clinical Trials are outsourced to CROs for cost-effective manufacturing and efficient Clinical Operations. Big Pharmaceutical Companies and Academic Institutes collaborate for innovative Drug Development Services. Advanced manufacturing technologies like Continuous Manufacturing and Digitalization are transforming the Pharmaceutical Ecosystem. Targeted Medication Therapies, Biosimilars, and Personalized Medicines are driving the need for Specialized Services and Cost-effective Manufacturing. Drug Delivery Systems and Clinical Trial Support are crucial for bringing Small Molecule Drugs and Active Pharmaceutical Ingredients to market. Regulatory bodies and industry associations play a vital role in ensuring Quality Control and ensuring the integrity of the Pharmaceutical Supply Chain. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

The pharmaceutical Contract Research and Manufacturing Organizations (CMOs) market in the Asia Pacific region holds the largest share but faces a significant challenge due to limited access to advanced technologies for manufacturing complex drugs, such as biological drugs and vaccines. These CMOs primarily focus on producing small molecule-based generic drugs due to high manufacturing costs and lack of funding. This restricts growth opportunities for small and medium-sized CMOs. Major players like Boehringer Ingelheim, Catalent, and Lonza dominate the market for large-scale production of biological drugs. The absence of advanced technologies and high manufacturing costs in countries like Mexico, South Korea, and Brazil also hinder the growth of CMOs in these regions. Consequently, the global pharmaceutical CRAM market growth may be impeded substantially during the forecast period.The Pharmaceutical Contract Research and Manufacturing (CRM) market faces several challenges in the production of biologics and small molecule drugs. Big Pharma companies and academic institutes rely on CROs for cost-effective manufacturing of targeted medication therapies, including biologics and biosimilars. Manufacturing services for active pharmaceutical ingredients (APIs) and drug formulation require advanced technologies like continuous manufacturing and specialized services for drug delivery systems. Quality control is crucial for producing consistent, high-quality products. CROs must support clinical trial operations and commercial operations, ensuring compliance with quality standards and patient needs. Digitalization and personalized medicines also require specialized expertise. The drug development process involves complex production workflows, from the creation of drug candidates to the manufacturing of oral solids, liquids, emulsions, and more. Meeting the demands of Big Pharma and academic institutes while maintaining cost-effectiveness and quality is a significant challenge for the CRM industry.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview

This pharmaceutical contract research and manufacturing market report extensively covers market segmentation by

Service 1.1 CMO1.2 CROEnd-user 2.1 Big pharmaceuticals2.2 Small and medium-sized pharmaceuticals2.3 Generic pharmaceuticalsGeography 3.1 North America3.2 Asia3.3 Europe3.4 Rest of World (ROW)

1.1 CMO-  The Contract Research and Manufacturing Organizations (CMOs) segment is the largest in the global pharmaceutical CRAM market, accounting for a significant market share. CMOs are entities that manufacture drugs and healthcare products on a contract basis for pharmaceutical companies and biotech firms. Advancements in medical sciences and the growing popularity of specialty medicines, as well as technological developments like nanotechnology and stem cell research, are driving the demand for complex manufacturing processes. These processes require extended resource deployments, leading pharmaceutical giants like Pfizer, Johnson & Johnson, and GlaxoSmithKline to outsource their manufacturing activities to optimize in-house resources. The outsourcing trend is particularly prevalent among pharmaceutical vendors worldwide, resulting in the substantial growth of the CMO segment. Emerging markets, including India, Brazil, China, and Mexico, are major contributors due to their low labor and land costs, making them attractive locations for setting up manufacturing facilities. Generic drug manufacturers in these countries outsource approximately 80% of their production to CMOs. The increasing focus on core competencies and cost reduction, along with the regulatory compliance and research advancement benefits, are fueling the expansion of the CMO segment in the global pharmaceutical CRAM market.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

The Pharmaceutical Contract Research and Manufacturing (CRM) market encompasses a range of services that support the development and production of small molecule drugs, biologics, biosimilars, and active pharmaceutical ingredients (APIs). Services include drug discovery, route scouting, regulatory compliance, clinical trials, outsourcing, drug formulation, quality control, and advanced manufacturing technologies such as continuous manufacturing and specialized services. Artificial Intelligence (AI) is increasingly being utilized in drug discovery to identify new drug candidates and optimize their properties. Cost-effective manufacturing is a key driver for outsourcing, particularly for generic drugs and APIs. Bioprocess outsourcing is essential for the production of complex biologics and biosimilars. Continuous manufacturing offers advantages in terms of cost savings, improved quality, and increased efficiency. Specialized services include the production of low potent APIs and the manufacturing of originator and generic APIs. The market caters to both small molecule drugs and biologics, with a focus on ensuring regulatory compliance and maintaining the highest standards of quality control.

Market Research Overview

The Pharmaceutical Contract Research and Manufacturing (CRM) market encompasses a range of services that support the entire drug development process, from discovery to commercialization. This market includes various services such as drug discovery, clinical trials, regulatory compliance, route scouting, bioprocess outsourcing, and manufacturing services. Generic Drugs: CRM companies offer manufacturing services for generic drugs, producing affordable alternatives to branded medicines. Artificial Intelligence: AI is increasingly used in drug development to identify new targets, optimize drug design, and analyze clinical trial data. Drug Development: CRM companies provide comprehensive drug development services, from discovery to commercialization, ensuring regulatory compliance and cost-effective manufacturing. Clinical Trials: CRM companies offer clinical trial support, managing trial design, execution, and data analysis to ensure efficient and effective trials. Outsourcing: Pharmaceutical companies outsource various aspects of drug development and manufacturing to CRM companies for cost savings and expertise. Bioprocess Outsourcing: CRM companies specialize in bioprocessing, producing biologics, biosimilars, and vaccines using advanced manufacturing technologies. Serialization and Counterfeiting: CRM companies provide serialization services to ensure product authenticity and combat counterfeiting, enhancing patient safety. Pharmaceutical Ecosystem: CRM companies operate within the complex pharmaceutical ecosystem, collaborating with academic institutes, CROs, and big pharma to bring new drugs to market. Drug Development Services: CRM companies offer a range of drug development services, from drug discovery and formulation to manufacturing and commercialization. Manufacturing Services: CRM companies provide manufacturing services for small molecule drugs, APIs, and drug delivery systems, ensuring quality control and cost savings. Cost-effective manufacturing: CRM companies offer cost-effective manufacturing solutions, utilizing economies of scale and advanced technologies to reduce production costs. Quality control: CRM companies prioritize quality control, implementing rigorous standards and advanced technologies to ensure product safety and efficacy. Advanced manufacturing technologies: CRM companies employ advanced manufacturing technologies, such as continuous manufacturing and specialized services, to improve efficiency and reduce costs. Personalized medicines: CRM companies support the development and manufacturing of personalized medicines, tailoring treatments to individual patient needs. Drug development processes: CRM companies optimize drug development processes, from production workflows to digitalization, to bring new drugs to market faster and more efficiently.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ServiceCMOCROEnd-userBig PharmaceuticalsSmall And Medium-sized PharmaceuticalsGeneric PharmaceuticalsGeographyNorth AmericaAsiaEuropeRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmaceutical-contract-research-and-manufacturing-market-to-grow-by-usd-141-3billion-from-2024-2028–driven-by-cost-efficient-resources-in-emerging-markets-ai-powered-report—technavio-302267668.html

SOURCE Technavio

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Youdao Dictionary Pen Unveils at CES 2025, Showcasing Cutting-Edge AI Innovations and Applications in Education

Published

8 minutes ago

on

January 10, 2025

By

LAS VEGAS, Jan. 10, 2025 /PRNewswire/ — Youdao, a leading intelligent learning company in China, is showcasing its AI-equipped smart device, the Youdao Dictionary Pen X7 series, at the International Consumer Electronics Show (CES 2025).This event showcases the strength of ‘Chinese AI’ in the field of educational technology to a global audience.

The Youdao booth attracted significant attention at the exhibition. The showcased Youdao Dictionary Pen X7 series features proprietary applications, including Hi Echo and Mr. P AI Tutor, which are based on the ‘Zi Yue’ educational large language model. It also provides offline translation capabilities through an edge-side large language model, drawing many users to experience the products.

During the exhibition, Youdao was invited to participate in the Microsoft Greater China offline event at CES 2025. Renlei Liu, Senior Vice President of Youdao, attended a high-level roundtable discussion. Alongside representatives from tech companies such as Microsoft, TCL, Lenovo, and TimeKettle, they explored AI innovation and the globalization of consumer electronics in China.

Renlei Liu stated that large language models possess exceptional natural language processing and interaction capabilities. Leveraging its extensive experience in the language and learning sectors, Youdao launched China’s first educational large language model, ‘Zi Yue’, in 2023. Based on this model, Youdao upgraded all of its software and hardware products and introduced a series of proprietary educational applications, including the digital human language coach, AI Document Q&A, and transcription services for international students.

Renlei Liu said, ‘We believe that before the emergence of truly super applications based on large language models, various companies are exploring vertical fields and specific scenarios, much like the early days of China’s mobile internet, when killer applications had not yet emerged and internet companies were innovating within vertical scenarios. There are many similarities between the era of large models and the mobile internet era, and we are actively experimenting as well’.

Youdao has also applied the reasoning and knowledge Q&A capabilities of the large language model to academic learning scenarios, launching the AI comprehensive inquiry learning assistant, Mr. P AI Tutor. It integrates the large language model and RAG (Retrieval-Augmented Generation) technology, enhancing the AI’s understanding of subject knowledge and the quality of its outputs. It offers guided explanations, multi-turn interactive heuristic teaching, and comprehensive Q&A support across all grades and subjects, addressing many issues in home tutoring scenarios.

Renlei Liu stated that Youdao is actively promoting the application of the “Zi Yue” educational large language model in various scenarios and has conducted a comprehensive AI upgrade of its business products to better meet users’ learning needs. As a result, Youdao’s AI subscription service has achieved rapid growth for seven consecutive quarters.

With the continuous development of large language model applications, improving the efficiency of AI research and development and application has become a key factor in industry competition. In response, Youdao has proposed a solution to harness the capabilities of smaller model applications. Renlei Liu pointed out that general large language models often aim for “large and comprehensive,” but the expansion of model size also leads to increased training and operational costs. For specific scenarios and tasks that require quick response times, using smaller models on the edge can facilitate more effective targeted training, enhance precision, and provide a better user experience.

The AI dictionary pen, equipped with a dedicated educational model can provide high-quality content and functional services, ensuring that it remains focused on learning purposes and is not used for entertainment or other applications. At the same time, by utilizing a smaller model on the edge for localized operation, it supports offline use, thereby avoiding disruptions from the network environment.

Renlei Liu stated that smaller models focus on high-quality vertical applications, which can continuously enhance user experience and build professional technical advantages through flexible and efficient training and iteration. Exploring the application of edge models in more specific scenarios is an important direction for Youdao’s development in AI technology.

In fact, Youdao has already made significant progress in the exploration of edge models. Based on its self-developed “Zi Yue” educational large language model, Youdao has developed the industry’s first edge large language model and applied it to the newly launched X7 series of dictionary pens. This dictionary pen features offline large language model translation capabilities, achieving translation results comparable to those of online NMT (Neural Machine Translation), greatly enhancing the accuracy and fluency of language learning.

As a star product in Youdao’s smart devices lineup, the Youdao Dictionary Pen X7 series has truly become an AI large language model dictionary pen. It is equipped with two proprietary applications of the first educational large language model, “Zi Yue” in China: the AI All-Subject Tutor, Mr. P AI Tutor, and the digital human language coach, Hi Echo, while also providing AI intelligent learning features such as AI essay refinement.

The Youdao Dictionary Pen X7 received an enthusiastic response from users upon its launch. It quickly became the best-selling product in the thousand-yuan price range, surpassing 30,000 units sold. During the 2024 Nov 11th Shopping Festival in China, the Youdao Dictionary Pen X7 Pro topped several industry rankings on major e-commerce platforms, marking the fifth consecutive year that Youdao dictionary pens have held the top position for sales in the same category across both JD.com and Tmall.

This time, Youdao showcased the Dictionary Pen X7 series at CES 2025, receiving widespread recognition on an international stage.

Focusing on AI + education, Youdao will continue to increase its investment in the research and development of edge model applications, promoting the implementation of large language models in more educational scenarios to provide learners with a better learning experience through efficient educational products.

About Youdao, Inc. 

Youdao, Inc. (NYSE: DAO) is a leading intelligent learning company in China focused on using technology to provide educational content, applications, and solutions for learners of all ages. Founded in 2006 as part of NetEase, Inc. (NASDAQ: NTES; HKEX: 9999), Youdao offers a wide range of online courses, interactive learning apps, and smart learning devices.

For more information, please visit: http://ir.youdao.com & https://smart.youdao.com/en/.

CONTACT: youdaopr@rd.netease.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/youdao-dictionary-pen-unveils-at-ces-2025-showcasing-cutting-edge-ai-innovations-and-applications-in-education-302347860.html

SOURCE Youdao

Continue Reading

Technology

HTX 2025 Outlook: Five Sectors to Look Forward to, and How Trump’s Policy Will Affect Crypto Industry

Published

8 minutes ago

on

January 10, 2025

By

SINGAPORE, Jan. 10, 2025 /PRNewswire/ — The year 2024 marks a significant chapter in the history of the crypto industry, where we witnessed continuous breakthroughs in blockchain technology, surges in Bitcoin price, and a gradually more open regulatory environment, with cryptocurrencies gaining increasing recognition from the mainstream. As 2025 unfolds, HTX, the world’s leading digital asset exchange, has released its latest report, HTX 2024 Global Web3 Blockchain Ecosystem Review and 2025 Outlook, which provides forward-looking insights into the development prospects of the crypto industry.

Key Sectors for 2025

In the report, HTX highlighted five key sectors that showed encouraging progress last year, and will continue to closely monitor these areas in 2025.

Bitcoin Ecosystem

In 2024, Bitcoin‘s market dominance kept increasing, solidifying its position as the core asset, with spot ETFs acting as liquidity channels, and U.S. listed companies such as MicroStrategy (MSTR) serving as the vehicles to absorb unlimited dollar liquidity.

As a result, it is increasingly essential to further develop Bitcoin‘s ecosystem and enhance capital utilization efficiency. With strong support from macro markets and infrastructure support, a further surge in Bitcoin demand over the next two years is well-anticipated.

Infrastructure

Infrastructure remained a cornerstone in 2024’s crypto investments and funding. The synergy between capital and technology has driven the rapid development of Layer 1, Layer 2,  and middleware projects, among others.

Layer 1 solutions, in particular, now represent the focal point of technical development and exploration within the crypto space, and it is expected to remain a priority for development resources and capital investment in the future.

Meme Coins

The Meme coin sector emerged as a hotspot in 2024, fostering community consensus while integrating with fields like DeFi and GameFi to create new use cases. As the crypto market environment grows increasingly favorable, more retail investors are expected to enter the market, positioning Meme projects as vital channels for capital inflows.

AI

In 2024, the intersection of Crypto and AI sector has been driving the exploration of several segmented fields, the hottest one of which is AI agents. In the future, AI agents will gradually become personal butlers and assistants for users, serving them with comprehensive capabilities. Over time, they may develop unique cultures and religions.

This deep integration of AI and encryption technology is a groundbreaking evolution that is unattainable within Web2 and cannot be achieved by Web3 relying solely on encryption technology.

TON Ecosystem

Attributable to Telegram’s hundreds of millions of users and robust technical support, the TON ecosystem achieved significant milestones in various fields, pioneering the monetization of Web2 social applications through crypto. Moving into 2025, it needs to explore and find new business models to improve user retention and identify its next growth curve.

Donald Trump Effect: Bitcoin Strategic Reserve Worth Anticipating

The report also discusses the potential impact of crypto-friendly policies that could arise after Donald Trump takes office. Two important bills, the FIT21 Act and the Bitcoin Strategic Reserve Act, are likely to pass more quickly thanks to him.

The FIT21 Act aims to create a clear legal framework for token issuance and trading by classifying tokens as digital assets or digital commodities, transferring the regulatory responsibilities of many blockchain projects from the SEC to the CFTC, and introducing a safe harbor mechanism. This would help standardize and promote the healthy growth of the entire industry.

The Bitcoin Strategic Reserve Act, aligning with Trump’s campaign promises, if passed, would mark Bitcoin‘s transition from a niche asset to a nationally recognized reserve asset, greatly enhancing its legitimacy and recognition. It may also prompt other countries to adopt similar measures to further advance Bitcoin‘s global recognition and application.

The Act was submitted to Congress for deliberation on August 4, 2024, and referred to the Senate Banking Committee for review. Trump is well-positioned to push this bill through. Meanwhile, several U.S. states have already proposed their own Bitcoin Strategic Reserve bills. By 2025, Bitcoin as a strategic reserve may become a reality.

Additionally, under Trump’s presidency, the SAB121 Act is likely to be repealed, allowing traditional financial institutions to hold cryptocurrencies on their balance sheets, further accelerating the institutionalization of crypto assets and contributing to the overall maturity of the crypto market. The SEC’s application criteria of the Howey Test may also be relaxed, increasing the likelihood of more spot crypto ETFs being approved and more public listings of crypto companies.

Meanwhile, the report also provides a comprehensive summary of 2024, looking back on the key events that had a major impact on the crypto industry while summing up what HTX had achieved over the last year.

To learn more, please visit: https://square.htx.com/htx-2024-global-web3-blockchain-ecosystem-review-and-2025-outlook/ 

About HTX

Founded in 2013, HTX has evolved from a virtual asset exchange into a comprehensive ecosystem of blockchain businesses that span digital asset trading, financial derivatives, research, investments, incubation, and other businesses.

As a world-leading gateway to Web3, we harbor global capabilities that enable us to provide users with safe and reliable services.

Our growth strategy – “Global Expansion, Thriving Ecosystem, Wealth Effect, Security & Compliance”, underpins our commitment to providing quality services and values to virtual asset enthusiasts worldwide.

Contact Details

Ruder Finn Asia
htx@ruderfinn.com 

Company Website
https://www.htx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/htx-2025-outlook-five-sectors-to-look-forward-to-and-how-trumps-policy-will-affect-crypto-industry-302347861.html

SOURCE HTX

Continue Reading

Technology

ZWSOFT 2024 Year in Review: Empowering Sustainable Innovation

Published

9 minutes ago

on

January 10, 2025

By

GUANGZHOU, China, Jan. 10, 2025 /PRNewswire/ — 2024 marked a transformative year for ZWSOFT, driven by its new mission: Empowering Sustainable Innovation. The ZWSOFT team took significant steps to drive innovation, foster collaboration, and deliver lasting value for customers, partners, and the global community.

From refining its all-in-one CAx solutions to fostering a thriving global ecosystem and nurturing talents, 2024 was a year of significant achievements and meaningful impact.

Refining All-in-One CAx Solutions for Global Professionals

In 2024, ZWSOFT unveiled the latest generation of its flagship products: ZWCAD 2025, ZW3D 2025, ZWCAD MFG 2025, PHOENICS 2025, and CADbro 2025. These releases introduced 45+ new features and 3,800+ enhancements, including powerful 3D capabilities, motion simulation, and AI-driven tools—all designed to deliver exceptional performance and empower professionals across industries.

These enhancements empower over 1.4 million users across 90+ countries, contributing to a 97.4% customer satisfaction rate in the company’s annual customer satisfaction survey. Throughout 2024, ZWCAD consistently earned recognition as a Leader and ranked among the top five in G2’s General-Purpose CAD category, solidifying its reputation as a reliable choice for designers and engineers worldwide.

Building Win-Win Partnerships for Greater Impact

ZWSOFT continued to build a vibrant global ecosystem based on collaboration, innovation, and shared success. The company’s flagship conference, ZWorld 2024, and prominent industry events such as Hannover Messe provided valuable platforms to connect with professionals worldwide and exchange insights on sustainable solutions for the AEC and manufacturing industries.

ZWSOFT further strengthened its global presence with five ZCON events held in Indonesia, Saudi Arabia, United Arab Emirates, Japan, and Vietnam, fostering stronger partnerships and unlocking new growth opportunities in key markets.

Collaboration remains at the core of ZWSOFT’s ecosystem. In 2024, the company partnered with over 260 global developers to deliver 300+ third-party applications and 430+ industry-specific solutions, tailored to address the unique needs of professionals across various industries.

Empowering Talents for a Sustainable Future

ZWSOFT’s commitment to nurturing future professionals and fostering innovation remained strong in 2024. The company collaborated with eight universities, providing software, equipment, and scholarships to support students and educators. The 2024 ZWSOFT CAD Competition attracted over 7,000 participants from 700+ universities, inspiring the next generation of designers and engineers.

ZWSOFT also continued to invest in its global workforce by launching the Overseas New Employee Training Program to help new team members integrate and thrive. Additionally, the company celebrated its people-first culture through ZWSOFT Family Day, bringing employees and their families together to foster a sense of community and recognize their contributions.

As 2025 begins, ZWSOFT remains committed to its mission of empowering sustainable innovation for businesses and individuals worldwide. With the strong foundation built in 2024, the company is poised to drive further progress, strengthen partnerships, and create a more sustainable future alongside its customers, partners, and employees.

Visit ZWSOFT’s 2024 Year in Review to learn more about the milestones that shaped an exceptional year.

About ZWSOFT

ZWSOFT aims to provide reliable all-in-one CAx (CAD/CAE/CAM) solutions for designers and engineers worldwide and enables them to streamline complex design workflows at a fair and reasonable price. Since ZWSOFT’s inception in 1998, over 1.4 million customers from more than 90 countries have chosen our products and solutions to solve their design challenges. Among the list are the world’s most innovative companies across various industries, including Saint-Gobain, LG, and Ericsson.

Website: https://www.zwsoft.com/ 

View original content to download multimedia:https://www.prnewswire.com/news-releases/zwsoft-2024-year-in-review-empowering-sustainable-innovation-302347866.html

SOURCE ZWSOFT CO., LTD. (Guangzhou)

Continue Reading

Trending